Description: Once upon a time, with enough advanced notice and a well-planned out meeting agenda, you could get all the Key Decision makers (KDMs) in the same conference room. Now, many companies have allowed KDMs to move to geographically diverse locations and this is no longer the norm. Has business been impacted? Have productivity and sales been impacted? We will discuss the significant changes that have occurred in our industry when we went from pre-COVID to a post-COVID virtual world. When key contacts and KDM's no longer come into the office 5 days per week, 8 hours each day, how do you visit their office in person? Do all the KDM's still live in close proximity to the office? Are hybrid meetings effective? How do you maintain frequency of contact? In-person, virtual? This will cover learnings, best practices, ways to spur productivity, comradery and new ways of working together more effectively. Sales managers and others can glean helpful insights that will make them more effective in working with and managing their client base.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: Learn from panelists from different companies as they come together to discuss their experiences.

Description: Given the rise in interest rates during 2023, the session will discuss the implication of increasing rates on FA and FIA business by looking at industry experience for FA and FIA products for 2023 and earlier years. Additionally, the session will walk through partial withdrawals, GLWB utilization, mortality and what to expect as interest rates volatile continues. The session will also discuss how direct writers and reinsurers are handing the inforce management aspects of these products in the uncertain and volatile economic periods.